Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Position Increased by Ameriprise Financial Inc.

Ameriprise Financial Inc. grew its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,182 shares of the medical research company’s stock after buying an additional 571 shares during the quarter. Ameriprise Financial Inc. owned about 0.12% of Bio-Rad Laboratories worth $11,229,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Venturi Wealth Management LLC raised its holdings in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after purchasing an additional 87 shares in the last quarter. GeoWealth Management LLC increased its position in shares of Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock worth $31,000 after acquiring an additional 72 shares in the last quarter. Picton Mahoney Asset Management grew its position in Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 35 shares in the last quarter. Asset Planning Inc purchased a new position in Bio-Rad Laboratories during the fourth quarter valued at approximately $33,000. Finally, UMB Bank n.a. grew its position in Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after acquiring an additional 32 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on BIO. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Royal Bank of Canada reduced their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. UBS Group dropped their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Citigroup dropped their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $327.40.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $248.45 on Monday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $215.38 and a fifty-two week high of $387.99. The firm has a market cap of $6.96 billion, a P/E ratio of -3.82 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The firm has a 50 day simple moving average of $243.46 and a 200 day simple moving average of $298.10.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The firm had revenue of $585.40 million for the quarter, compared to analysts’ expectations of $573.01 million. During the same period last year, the firm earned $2.30 earnings per share. The business’s revenue for the quarter was down 4.2% on a year-over-year basis. Sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.